Beyond Comorbidity: A Three-Level Clinical Framework for Endocrine–Metabolic Associations in Rosacea
- 1Department of Ear Reconstruction, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
- 2Laser Aesthetic Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
- 3Department of Cosmetic Injection Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
Abstract
Rosacea has been increasingly associated with endocrine–metabolic abnormalities, but the clinical significance of these findings remains uncertain because existing studies evaluate biologically distinct outcomes, ranging from isolated biomarkers to clinically diagnosed endocrine disease. In this narrative review, we synthesize evidence across the thyroid, insulin–metabolic, gonadal and hypothalamic–pituitary–adrenal axes using a three-level framework that distinguishes biomarker-level signals, functional or contextual processes, and overt endocrine disease. Overall, the available evidence appears more coherent for functional or contextual processes than for established endocrine disorders. Insulin resistance and individual metabolic abnormalities are reported more consistently than diabetes mellitus or metabolic syndrome, thyroid-related findings remain heterogeneous, and gonadal and hypothalamic–pituitary–adrenal associations are better interpreted in terms of hormonal, vasomotor and stress-related context than persistent endocrine dysfunction. Vascular, immune-inflammatory, oxidative and neuroendocrine pathways provide biological plausibility for these associations, although causal evidence remains limited. We therefore propose that endocrine–metabolic factors may be better conceptualized as heterogeneous contextual modifiers of rosacea expression rather than as a uniform group of causal comorbidities. Current evidence does not support routine endocrine investigation solely because of rosacea; assessment should follow conventional clinical indications. Prospective, phenotype-stratified studies are needed to validate this framework and determine whether these proposed modifiers predict disease activity, phenotype or treatment response.
Related
- Data-driven endocrine–metabolic phenotypes in young women with polycystic ovary syndrome and associations with cardiometabolic risk markers
- Stressful life events recorded in 39.7 million clinical notes: associations with mental disorders, comorbidity, and frailty
- Endocrine and metabolic profiling of PMOS rat models in relation to clinical obese and non-obese phenotypes
- Associations of Coexisting Metabolic Dysfunction‐Associated Steatotic Liver Disease and Sarcopenia‐Related Abnormalities With Adverse Clinical Outcomes Across Obesity States
- Dysfunctional Sleep Beliefs and Attitudes in Major Depressive Disorder: Dimensional Associations with Clinical Phenotypes and Gut-Neuroimmune-Metabolic-Oxidative Pathways
BibTeX
@article{li2026beyond,
title = {{Beyond Comorbidity: A Three-Level Clinical Framework for Endocrine–Metabolic Associations in Rosacea}},
author = {Benjie Li and Ximeng Jia and Ronghao Ouyang and Yutong Liang and Mengzhe Qin and Tun Liu and Jintian Hu},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
month = oct,
doi = {10.2147/ccid.s649960},
url = {https://doi.org/10.2147/ccid.s649960},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Beyond Comorbidity: A Three-Level Clinical Framework for Endocrine–Metabolic Associations in Rosacea
AU - Benjie Li
AU - Ximeng Jia
AU - Ronghao Ouyang
AU - Yutong Liang
AU - Mengzhe Qin
AU - Tun Liu
AU - Jintian Hu
PY - 2026
DA - 2026/10/30
JO - Clinical, Cosmetic and Investigational Dermatology
DO - 10.2147/ccid.s649960
UR - https://doi.org/10.2147/ccid.s649960
AB - Rosacea has been increasingly associated with endocrine–metabolic abnormalities, but the clinical significance of these findings remains uncertain because existing studies evaluate biologically distinct outcomes, ranging from isolated biomarkers to clinically diagnosed endocrine disease. In this narrative review, we synthesize evidence across the thyroid, insulin–metabolic, gonadal and hypothalamic–pituitary–adrenal axes using a three-level framework that distinguishes biomarker-level signals, functional or contextual processes, and overt endocrine disease. Overall, the available evidence appears more coherent for functional or contextual processes than for established endocrine disorders. Insulin resistance and individual metabolic abnormalities are reported more consistently than diabetes mellitus or metabolic syndrome, thyroid-related findings remain heterogeneous, and gonadal and hypothalamic–pituitary–adrenal associations are better interpreted in terms of hormonal, vasomotor and stress-related context than persistent endocrine dysfunction. Vascular, immune-inflammatory, oxidative and neuroendocrine pathways provide biological plausibility for these associations, although causal evidence remains limited. We therefore propose that endocrine–metabolic factors may be better conceptualized as heterogeneous contextual modifiers of rosacea expression rather than as a uniform group of causal comorbidities. Current evidence does not support routine endocrine investigation solely because of rosacea; assessment should follow conventional clinical indications. Prospective, phenotype-stratified studies are needed to validate this framework and determine whether these proposed modifiers predict disease activity, phenotype or treatment response.
SN - 1178-7015
ER -